Article
Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial.
European urology oncology - 1 Oct 2023
Shore Neal, Gazi Mukaram, Pieczonka Christopher, Heron Sean, Modh Rishi, Cahn David, Belkoff Laurence H, Berger Aaron, Mazzarella Brian, Veys Joseph, Idom Charles, Morris David, Jayram Gautam, Engelman Alexander, Bukkapatnam Raviender, Dato Paul, Bevan-Thomas Richard, Cornell Robert, Wise David R, Hardwick Mary Kay, Hernandez Ryan D, Rojahn Susan, Layman Paige, Hatchell Kathryn E, Heald Brandie, Nussbaum Robert L, Nielsen Sarah M, Esplin Edward D
Abstract excerpt
BACKGROUND: Prostate cancer (PCa) patients with pathogenic/likely pathogenic germline variants (PGVs) in cancer predisposition genes may be eligible for U.S. Food and Drug Administration-approved targeted therapies, clinical trials, or enhanced screening. Studies suggest that eligible patients are missing genetics-informed care due to restrictive testing criteria. OBJECTIVE: To establish the prevalence of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.